Cannabinoid Emulsifier

Abstract

Provided herein is a compound which is particularly suitable for use as a cannabinoid, as an emulsifier for a cannabinoid, in a formulation comprising the compound and in a method of treatment using the compound. The compound is defined by the General Formula: wherein: R1-R10 are independently selected from H or an alkyl of 1-10 carbons; alkenyl of up to 10 carbons; or groups on adjacent carbons may be taken together to form an alkene; R11 and R12 are independently H or —(CH2CHR16O)x—R17 with the proviso that at least one of R11 or R12 represents —(CH2CHR16O)xR17—; R11 and R10 may be taken together to represent —C(R19)2—; R13-R15 independently represent H or an alkyl of 1-8 carbons; each R16 independently represents H or an alkyl of 1-3 carbons; each R17 independently represents H, an alkyl or substituted alkyl of 1-22 carbons, aryl or substituted aryl or the ester of an acid; each R19 independently represents H or an alkyl of 1-5 carbons; and each x is independently an integer of 1-100.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the priority of pending U.S. Provisional Application No. 63/114,010 filed Nov. 16, 2020 which is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention is related to an improved cannabinoid emulsifier, particularly cannabidiol (CBD). More specifically, the present invention is related to an ethoxylated cannabinoid emulsifier which is particularly suitable for emulsifying cannabinoids and particularly CBD.

BACKGROUND

Cannabidiol (CBD) is an oily cannabinoid first discovered in Cannabis extracts in 1940. CBD is produced from the flowers, leaves, and stalks of the Cannabis sativa plant. CBD accounts for up to 40% of the plant extract but does not contain tetrahydrocannabinol (THC). This extract is frequently diluted with hemp seed oil, olive oil, or other types of carrier oils. CBD enriched oil products are non-psychoactive and typically contain ˜20% CBD.

In 2012, Israeli scientists identified more than 1,200 human genes affected by CBD wherein 600 gene transcripts were upregulated by CBD and 524 were downregulated. CBD has also been shown to regulate the expression of 491 genes with 165 of the genes being in skin.

CBD, as most cannabinoids, has very low water solubility. Therefore, to incorporate CBD into a water-based formulations, such as cosmetic formulations, an emulsifier system must be used. The art contains a number of examples of CBD formulations. Relevant references are discussed herein.

US Publ. Appl. No. 2019298683, which is incorporated herein by reference, teaches a high concentration self-emulsifying formulation comprising: (i) about 20% to about 90% by weight of a cannabinoid or mixture of cannabinoids; (ii) about 5% to about 50% by weight of a terpene or terpene mixture, and (iii) about 5% to about 50% by weight of an emulsifier or emulsifier mixture. The teachings are specific to a pharmaceutical composition or mixture that self-emulsifies in an aqueous medium to produce a plurality of particles having an average particle size of about 100 microns to about 10 nm. The emulsifier includes polysorbate 80, oleoyl polyoxyl-6 glyceride, polyoxyl 35 hydrogenated castor oil, sucrose distearate, tocopherol polyethylene glycol 1000 succinate, lauroyl polyoxyl-32 glyceride, sorbitan monooleate, salts thereof and derivatives thereof.

US Publ. Appl. No. 20100273895, which is incorporate herein by reference, teaches cannabidiol formulations and methods of use. Specifically taught is a pharmaceutical composition comprising: (A) 1-10% (wt/wt) cannabidiol based on the composition; (B) 40% to 61% (wt/wt) ethanol relative to the composition; (C) 2.5% to 10% (wt/wt) diethylene glycol monoethyl ether relative to the composition; (D) 5% to 20% (wt/wt) propylene glycol based on the composition; (E) 0.1% to 3% (wt/wt) isopropyl myristate relative to the composition; and (f) an amount of water sufficient to bring the composition to a total of 100% (wt/wt).

US Publ. Appl. No. 2015342902, which is incorporated herein by reference, teaches specific cannabinoid formulations. Specifically taught is an oral pharmaceutical formulation comprising: cannabidiol and caprylic/capric triglyceride, wherein the formulation provides a greater cannabidiol Cmax, AUC(O-inf) and/or AUC (0-t) when administered to a subject in a fed condition than when administered to a subject in a fasted condition.

U.S. Publ. App. No. 20180042845, which is incorporated herein by reference, is specific to preparations of cannabis emulsions and methods thereof. More specifically taught is a composition comprising phospholipids, or derivatives thereof, and an oily fraction. The composition is formulated as an emulsion; wherein the oily fraction contains about 50% cannabinoids.

WO 2019135225A1, which is incorporated herein by reference, teaches solid self-emulsifying cannabinoid compositions. More specifically, the teachings are directed to a solid self-emulsifying cannabinoid composition, comprising: a) from about 0.1% to about 30% by weight of at least one cannabinoid or a mixture thereof, b) from about 1.0% to about 5% by weight of at least one essential oil or at least one terpene or a mixture thereof, c) from about 1% to about 40% of at least two emulsifiers, and d) from about 40% to about 90% of at least one adsorbing powder. At least one cannabinoid is essentially solubilized in the mixture of the at least one terpene, at least one essential oil and at least two emulsifiers. The resulting mixture is adsorbed onto the at least one adsorbing powder affording a solid self-emulsifying composition. The solid composition self emulsifies upon contact with water or mammal's body fluids to produce an oil-in-water sub-micron emulsion comprising a plurality of particles having a mean particle size of from about 10 nm to about 1,000 nm. WO 2019135225A1 also teaches that at least one of the emulsifiers is selected from non-ionic surfactants with HLB of about 10 to about 16 and the other(s) emulsifier is selected from non-ionic hydrophilic or hydrophobic surfactants having a HLB value of about 2 to about 12. WO 2019135225A1 also teaches that the hydrophilic emulsifier has an HLB from about 10 to about 16 and is selected from the group consisting of sucrose ester, sucrose stearate, sucrose laurate, sucrose oleate, polysorbate, polyoxyl hydrogenated castor oil, polyoxyl castor oil, tocopherol polyethylene glycol 1000 succinate, poly glyceryl fatty acid ester and combinations thereof and mixtures thereof, in a concentration of from about 1% w/w to about 20% w/w, preferably from about 2% w/w to about 10% w/w. WO 2019135225A1 also teaches that at least one emulsifier has an HLB from about 2 to about 12 and is selected from the group consisting of sorbitan fatty acid esters, sorbitan monooleate, sorbitan stearate, sorbitan oleate, sucrose ester, sucrose di and tri stearate, polyglyceryl fatty acid esters, polyglyceryl-3 dioleate, fatty acids esters and ethers, steareth-2, oleth-2, ceteth-2, salts thereof, derivatives thereof, and combinations thereof.

In spite of the extensive efforts, there is still a need for a better emulsifier for liquid cannabinoid, particularly CBD, formulations. The ideal emulsifier would be highly compatible with CBD, be nonionic in nature so it will be compatible with either anionic or cationic components in a skin care formulation, and be unaffected by the presence of water or other formulation components. An improved emulsifier, based on ethoxylated cannabinoids, is provided herein.

SUMMARY OF THE INVENTION

The present invention is related to an improved emulsifier which can provide the biological benefits of a cannabinoid.

A particular feature of the present invention is the ability to emulsify cannabinoids thereby providing for formulations, and particularly aqueous formulations, comprising cannabinoids.

These and other advantages, as will be realized, are provided in a compound defined by the General Formula:

wherein:
R¹-R¹⁰ are independently selected from H or an alkyl of 1-10 carbons; alkenyl of up to 10 carbons; or groups on adjacent carbons may be taken together to form an alkene; R¹¹ and R¹² are independently H or —(CH₂CHR¹⁶O)_x—R¹⁷ with the proviso that at least one of R¹¹ or R¹² represents —(CH₂CHR¹⁶O)_xR¹⁷—; R¹¹ and R¹⁰ may be taken together to represent —C(R¹⁹)²—;
R¹³-R¹⁵ independently represent H or an alkyl of 1-8 carbons;
each R¹⁶ independently represents H or an alkyl of 1-3 carbons;
each R¹⁷ independently represents H, an alkyl or substituted alkyl of 1-22 carbons, aryl or substituted aryl or the ester of an acid;
each R¹⁹ independently represents H or an alkyl of 1-5 carbons; and
each x is independently an integer of 1-100.

Yet another embodiment is provide in formulation comprising:

a compound defined by General Formula:

wherein:
R¹-R¹⁰ are independently selected from H or an alkyl of 1-10 carbons; alkenyl of up to 10 carbons; or groups on adjacent carbons may be taken together to form an alkene;
R¹¹ and R¹² are independently H or —(CH₂CHR¹⁶O)_x—R¹⁷ with the proviso that at least one of R¹¹ or R¹² represents —(CH₂CHR¹⁶O)_xR¹⁷—; R¹¹ and R¹⁰ may be taken together to represent —C(R¹⁹)²—;
R¹³-R¹⁵ independently represent H or an alkyl of 1-8 carbons;
each R¹⁶ independently represents H or an alkyl of 1-3 carbons;
each R¹⁷ independently represents H, an alkyl or substituted alkyl of 1-22 carbons, aryl or substituted aryl or the ester of an acid;
each R¹⁹ independently represents H or an alkyl of 1-5 carbons; and
each x is independently an integer of 1-100; and
a cannabinoid.

Yet another embodiment is provided in a method for treating tissue comprising applying a formulation comprising:

a compound defined by General Formula:

wherein:
R¹-R¹⁰ are independently selected from H or an alkyl of 1-10 carbons; alkenyl of up to 10 carbons; or groups on adjacent carbons may be taken together to form an alkene; R¹¹ and R¹² are independently H or —(CH₂CHR¹⁶O)_x—R¹⁷ with the proviso that at least one of R¹¹ or R¹² represents —(CH₂CHR¹⁶O)_xR¹⁷—; R¹¹ and R¹⁰ may be taken together to represent —C(R¹⁹)²—;
R¹³-R¹⁶ independently represent H or an alkyl of 1-8 carbons;
each R¹⁶ independently represents H or an alkyl of 1-3 carbons;
each R¹⁷ independently represents H, an alkyl or substituted alkyl of 1-22 carbons, aryl or substituted aryl or the ester of an acid;
each R¹⁹ independently represents H or an alkyl of 1-5 carbons; and
each x is independently an integer of 1-100; and
a cannabinoid.

DESCRIPTION

The instant invention is specific to an emulsifier which is the poly(alkyleneoxide) ethers of cannabinoids, represented by the General Formula. The emulsifier is formed from the reaction of preferably, ethylene oxide (EO) or propylene oxide (PO) with a cannabinoid and particularly CBD. The resulting emulsifier is nonionic in character. Depending on the ratio of EO and PO to CBD, as a representative cannabinoid, the water solubility can be adjusted higher or lower. More EO will make the resulting emulsifier more water soluble and adjust its emulsifying power. Using CBD as the representative hydrophobe of the emulsifier ensures excellent compatibility with the native compound or free CBD oil. The ether linkages of the emulsifier are resistant to hydrolysis and thus the emulsifier is indefinitely stable in water and in the presence of other formulation components.

The emulsifier is represented by General Formula:

wherein:
R¹-R¹⁰ are independently selected from H or an alkyl of 1-10 carbons; alkenyl of up to 10 carbons; or groups on adjacent carbons may be taken together to form an alkene;
R¹, R⁵, R⁶, R⁷, R⁸ and R⁹ are preferably H; R² and R³ are preferably taken together to form an alkene; R⁴ is preferably —CH₃; R¹⁹ is preferably —C(═CH₂)CH₃;
R¹¹ and R¹² are independently H or —(CH₂CHR¹⁶O)_x—R¹⁷ with the proviso that at least one of R¹¹ or R¹² represents —(CH₂CHR¹⁶O)_xR¹⁷—; R¹¹ and R¹⁰ may be taken together to represent —C(R¹⁹)²—;
R¹³-R¹⁵ independently represent H or an alkyl of 1-8 carbons; R¹³ and R¹⁴ are preferably H; R¹⁵ is preferably an alkyl of 1-8 carbons and more preferably —(CH₂)₄CH₃;
each R¹⁶ independently represents H or an alkyl of 1-3 carbons; each R¹⁶ preferably independently represents H or —CH₃;
each R¹⁷ independently represents H, an alkyl or substituted alkyl of 1-22 carbons, aryl or substituted aryl; alternatively R¹⁷ is the ester of an acid, —C(O)—R¹⁸, wherein each R¹⁸ preferably represents the remnant of an acid or ester preferably salicylic acid, methyl salicylate, a carboxylic acid of 5 to 10 carbons, cinnamic acid, citric acid, retinoic acid, and ascorbic acid. In an embodiment R¹⁸ represents the remnant of a C1-C22 organic acid or ester wherein C1-C22 represents 1-22 carbons which are preferably alkyl carbons.
each R¹⁹ independently represents H or an alkyl of 1-5 carbons; each R¹⁹ is preferably —CH₃;
each x is independently an integer of 1-100 and preferably 3-13.

A particularly preferred emulsifier of the General Formula is represented by Formula I:

In a particularly preferred embodiment of Formula I, each x is independently 3-13 and each R¹⁷ is independently selected from H, C(O)C₆H₄OH, —C(O)CH═CHC₆H₆, —C(O)(CH₂)₇CH₃, or —C(O)(CH₂)₉CH₃ and preferably both R¹⁷ groups are the same.

Another particularly preferred embodiment of the General Formula is represented by Formula II:

In a particularly preferred embodiment of Formula II, each x is independently 3-13 and each R¹⁷ is independently selected from H, C(O)C₆H₄OH, —C(O)CH═CHC₆H₅, —C(O)(CH₂)₇CH₃, or —C(O)(CH₂)₉CH₃ and preferably both R¹⁷ groups are the same.

For substituent —C(O)—R¹⁸, each R¹⁸ preferably represents the remnant of an acid or ester. By way of a clarifying non-limiting example, for an acid or ester, generally represented by R—C(O)OX wherein X is H or an alkyl, R¹⁸ would be the remnant, R, remaining after esterification. Particularly preferred acids or esters include salicylic acid or methyl salicylate wherein R¹⁷ is —C(O)C₆H₄OH, a carboxylic acid of 6 to 10 carbons wherein R¹⁷ is —C(O)(CH₂)_5-9CH₃ or cinnamic acid wherein R¹⁷ is —C(O)CH═CHC₆H₅. Other acids or ester suitable for demonstration of the invention are C1-C22 organic carboxylic acids.

The ether groups, —(CH₂CHR¹⁶O)_xR¹⁷—, alter the hydrophilic-lipophilic balance (HLB) of the emulsifier with a higher number of —CH₂CHR¹⁶O— groups being consistent with a higher HLB. An HLB of at least 8 is preferred with and HLB of 12-16 being more preferred.

The emulsifier is particularly suitable for emulsifying cannabinoid in a formulation and particularly an aqueous formulation comprising cannabinoids. Cannabinoids are marginally soluble, if soluble at all, in aqueous solutions and the instant emulsifier allows the cannabinoid to be utilized in an aqueous formulation. A preferred formulation comprises at least 1 wt % to 99 w % emulsifier with the balance being selected from solvents, oils, surfactants, cannabinoid.

A preferred solvent is water with other solvents being suitable for demonstration of the invention. Other suitable solvents include alcohols.

Oils, particularly natural oils or their alkyl esters, are particularly suitable for use with the invention. Particularly suitable oils include glycerides such as monoglycerides, diglycerides and particularly triglycerides. Particularly preferred oils include coconut oil, olive oil and hempseed oil.

The emulsifier is particularly suitable for use in a cosmeceutical for use in acne regulation, cell renewal and regeneration, epidermal barrier formulations, extracellular matrix integrity formulations, pigmentation regulation or melanogenesis, for skin hydration, tissue remodeling, wound healing, insulin signaling, pain treatment, inflammation mitigation, immune response, circadian rhythm treatments, anti-oxidant stress relief, CB1 partial agonist, emollient or humectant, skin brightening, as a barrier cream, as a skin protectant, and as a sun protection factor (SPF) enhancer, as a film former, or as a fragrance fixative.

A particularly preferred formulation comprises the emulsifier and a cannabinoid obtained from cannabis. Particularly preferred cannabinoids are selected from the group consisting of CBD, THC, cannabichromene (CBC), cannabichromevarin (CBCV), cannabidiphorol (CBDP), cannabidivarinic acid (CBDVA), cannabielsoin (CBEA), cannabigerolic acid (CBCA), cannabigerolic acid monomethyl ether (CBGAM), cannabigerovarinic acid (CBGVA), cannabicyclolic acid (CBLA), cannabinolic acid (CBNA), cannabicitranic acid (CBTA), cannabivarinic acid (CBVA), tetrahydrocannabinolic acid (THCA), tetrahydrocannabiorcolic acid (THCCA), tetrahydrocannabiphorolic acid (THCPA), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), cannadibiphorol (CBDP), cannabidivarin (CBDV), cannabielsoin (CBE), cannabigerol (CBG), cannabigerol monomethylether (CBGM), cannabigerovarin (CBG), cannabigerol monomethylether (CBGM), cannabigerovarin (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabicitran (CBTC), cannabivarin (CBV), tetrahydrocannabiorcol (THCC), tetrahydrocannabiphorol (THCP) or tetrahydrocannabivarin (TNCV). Other products from cannabis may be used in combination with the emulsifier such as hemp.

The emulsifier is specifically suitable for use in treating tissue, and particularly skin applications and oral applications wherein a formulation is applied to the skin or administered orally. A preferred formulation comprises water, a compound of the General Formula, a cannabinoid with cannabidiol or tetrahydrocannabinol being particularly preferred, and optional additives such as surfactants, emollients, lubricants, fragrances, colorants, flavorants, medications and the like.

The method of applying the formulation is not limited herein. The formulation may be applied by spraying, dripping, dipping or pouring the formulation onto the tissue to be treated. Alternatively, the formulation may be applied by an applicator such as by painting or wiping.

While not limited to theory, it is hypothesized that the emulsifier has similar biological activity to the native compound. For the purposes of this invention, the term native compound refers to a compound of the General Formula wherein R¹¹ and R¹² are H. By way of example, Formula I with x being zero and R¹⁷ being H is CBD and Formula II with x being zero and R¹⁷ being H is THC. By increasing the hydrophilicity of the native compound, to form the emulsifier, the emulsifier is better able to cross various mucosal membranes or the blood-brain barrier, thereby altering the biological effect. The emulsifier is therefore suitable to be used alone or the emulsifier can be used in combination with the native compound or a different cannabinoid.

The method of forming the emulsifier is not particularly limited with each step being well within the range of knowledge of those of skill in the art. The polyether groups are formed by typical ring opening reaction of ethylene oxide, or a derivative, in the presence of a catalyst as is well known in the art. The formation of the ester by the reaction of an alcohol and carboxylic acid is well known chemistry which is very familiar to those of skill in the art.

EXAMPLES

General Reaction Scheme

The esterification of CBD ethoxylate, as a representative cannabinoid, was conducted with a nitrogen sparge at elevated temperatures 170° C.). Two catalysts were employed for these reactions, either hypophosphorous acid, particularly for cinnamate and capric/caprylate, or titanium (IV) butoxide, particularly for salicylate. CBD has two free hydroxyls, which were ethoxylated and subsequently esterified. Therefore, the reactions were conducted in a 2:1 molar ratio, with the acid to be esterified in excess. It should be noted that the salicylate ester was prepared via transesterification with methyl salicylate, producing methanol as a by-product. One of skill in the art would realize the adjustments in molar ratios and conditions for other cannabinoids and acids.

Synthesis of Cinnamate-Ester of CBD Ethoxylate

The reaction was conducted in a 3000 mL reaction flask, equipped with a heating mantle, temperature probe, overhead agitation, nitrogen sparge and a condenser. For a typical reaction, 1,279 g of CBD ethoxylate, 719 g trans-cinnamic acid and 2.0 g of hypophosphorous acid were added to the reaction flask. Under agitation and nitrogen sparge, the reaction was heated to 220° C. and held under constant agitation overnight. The reaction was then cooled to room temperature.

Synthesis of Caprate/Caprylate-Ester of CBD Ethoxylate

The reaction was conducted in a 3000 mL reaction flask, equipped with a heating mantle, temperature probe, overhead agitation, nitrogen sparge and a condenser. For a typical reaction, 1,575 g of CBD ethoxylate, 922 g Capric/Caprylic acid and 2.5 g of hypophosphorous acid were added to the reaction flask. Under agitation and nitrogen sparge, the reaction was heated to 190° C. and held, under constant agitation overnight. The reaction was then cooled to room temperature.

Synthesis of Salicylate-Ester of CBD Ethoxylate

The reaction was conducted in a 3000 mL reaction flask, equipped with a heating mantle, temperature probe, overhead agitation, nitrogen sparge and a condenser. For a typical reaction, 1,208 g (2.1 moles) of CBD ethoxylate, 791 g methyl salicylate (5.2 moles) and 1.0 g of titanium (IV) butoxide were added to the reaction flask. Under agitation and nitrogen sparge, the reaction was heated to 170° C. and held under constant agitation overnight. The reaction was then cooled to room temperature.

Synthesis of Retinoate-Ester of CBD Ethoxylate

The reaction would be conducted in a 3000 mL reaction flask, equipped with a heating mantle, temperature probe, overhead agitation, nitrogen sparge and a condenser. For a typical reaction, 1,208 g (2.1 moles) of CBD ethoxylate, 1,352 g retinoic acid (4.5 moles) and 2.5 g of hypophosphorous acid would be added to the reaction flask. Under agitation and nitrogen sparge, the reaction would be heated to 170° C. and held, under constant agitation overnight. The reaction would then be cooled to room temperature.

Synthesis of Citrate-Ester of CBD Ethoxylate

The reaction would be conducted in a 3000 mL reaction flask, equipped with a heating mantle, temperature probe, overhead agitation, nitrogen sparge and a condenser. For a typical reaction, 1,208 g (2.1 moles) of CBD ethoxylate, 864 g citric acid (4.5 moles) and 2.5 g of hypophosphorous acid would be added to the reaction flask. Under agitation and nitrogen sparge, the reaction would be heated to 170° C. and held, under constant agitation overnight. The reaction would then be cooled to room temperature.

Example 1

300 g of CBD isolate was charged to a pressure vessel and 0.1% KOH catalyst was added. After removing all water and air, the mixture was heated to 110-120° C. and 900 g of ethylene oxide (EO) was added over 7-8 hours. After EO addition was complete, the reactor was held at temperature until all of the EO was consumed. Trace EO and 1,4-dioxane were then removed using vacuum. The reactor contents were cooled and acetic acid was added to neutralize the catalyst and bring the pH into the 6-7 range. The resulting product was polyoxyethylene (21) CBD.

Example 2

10 g of CBD and 1.5 g of the product obtained by Example 1 were combined and the mixture added to 90 g of water with stirring. The CBD was emulsified and formed a clear emulsion.

Example 3

A first vessel was charged with deionized water (88.0 wt %), caprylyl glycol (1.0 wt %) and CannaSorb CBD-Active (1.0 wt %) followed by heating to 80° C. A second vessel was charged with Cannasorb LC (1.5 wt %) and Cannasol CBD-S (1.5 wt %) followed by heating to 80° C. with mixing until uniform. Using a homomixer at slow spead the components of the first vessel were added to the second vessel resulting in a lotion which thickened with increased addition of the water phase. The lotion was cooled to 35° C. followed by addition of a mixture of an Essential Oil Blend (0.3 wt %) comprising Eucalyptus Oil, Thyme Oil and Rosemary Oil and Vitacon ACE (0.2 wt %) comprising Vitamins A, C and E to obtain a formulation. Caprylyl glycol was obtained from Inolex. CannaSorb CBD-Active, Cannasorb LC and Cannasol CBD-S were obtained from Synergy Life Sciences Inc. The essential oil blend was obtained from Essential Ingredients Inc.

The formulation of Example 3 provided reduced pain and inflammation while providing skin rejuvenation.

The invention has been described with reference to preferred embodiments without limit thereto. One of skill in the art would realize additional embodiments which are described and set forth in the claims appended hereto.

Claims

1. A compound defined by the General Formula:

wherein:

R1-R10 are independently selected from H or an alkyl of 1-10 carbons; alkenyl of up to 10 carbons; or groups on adjacent carbons may be taken together to form an alkene;

R11 and R12 are independently H or —(CH2CHR16O)x—R17 with the proviso that at least one of R11 or R12 represents —(CH2CHR16O)xR17—; R11 and R10 may be taken together to represent —C(R19)2—;

R13-R15 independently represent H or an alkyl of 1-8 carbons;

each R16 independently represents H or an alkyl of 1-3 carbons;

each R17 independently represents H, an alkyl or substituted alkyl of 1-22 carbons, aryl or substituted aryl or the ester of an acid;

each R19 independently represents H or an alkyl of 1-5 carbons; and

each x is independently an integer of 1-100.

2. The compound of claim 1 wherein R1, R5, R6, R7, R8 and R9 are H.

3. The compound of claim 1 wherein R2 and R3 are taken together to form an alkene.

4. The compound of claim 1 wherein R4 is —CH3.

5. The compound of claim 1 wherein R19 is —C(CH2)CH3.

6. The compound of claim 1 wherein R13 and R14 are H;

7. The compound of claim 1 wherein R15 is an alkyl of 1-8 carbons.

8. The compound of claim 7 wherein R15 is —(CH2)4CH3.

9. The compound of claim 1 wherein each R16 independently represents H or —CH3.

10. The compound of claim 1 wherein R17 is C(O)R18 wherein R18 represents the remnant of an acid or ester.

11. The compound of claim 10 wherein R18 represents the remnant of salicylic acid, methyl salicylate, a carboxylic acid of 5 to 10 carbons, cinnamic acid, citric acid, retinoic acid, acetic acid, ascorbic acid, capric acid, and caprylic acid.

12. The compound of claim 1 wherein each R19 is —CH3.

13. The compound of claim 1 wherein each x is independently an integer of 3-13.

14. The compound of claim 1 wherein said compound is defined by Formula I:

15. The compound of claim 14 wherein each x is independently 3-13 and each R17 is independently selected from H, C(O)C6H4OH, —C(O)CH═CHC6H5, —C(O)(CH2)7CH3, or —(O)(CH2)9CH3.

16. The compound of claim 15 wherein both R17 groups are the same.

17. The compound of claim 1 wherein said compound is defined by Formula II:

18. The compound of claim 17 wherein each x is independently 3-13 and each R17 is independently selected from H, C(O)C6H4OH, —C(O)CH═CHC6H5, —C(O)(CH2)7CH3 or —(O)(CH2)9CH3.

19. The compound of claim 18 wherein both R17 groups are the same.

20. The compound of claim 1 having an HLB of at least 8.

21. The compound of claim 20 wherein said HLB of 12-16.

22. A formulation comprising:

a compound defined by General Formula:

wherein:

R1-R10 are independently selected from H or an alkyl of 1-10 carbons; alkenyl of up to 10 carbons; or groups on adjacent carbons may be taken together to form an alkene;

R11 and R12 are independently H or —(CH2CHR16O)x—R17 with the proviso that at least one of R11 or R12 represents —(CH2CHR16O)xR17—; R11 and R10 may be taken together to represent —C(R19)2—;

R13-R15 independently represent H or an alkyl of 1-8 carbons;

each R16 independently represents H or an alkyl of 1-3 carbons;

each R17 independently represents H, an alkyl or substituted alkyl of 1-22 carbons, aryl or substituted aryl or the ester of an acid;

each R19 independently represents H or an alkyl of 1-5 carbons; and

each x is independently an integer of 1-100; and

a cannabinoid.

23. The formulation of claim 22 wherein R1, R5, R6, R7, R8 and R9 are H.

24. The formulation of claim 22 wherein R2 and R3 are taken together to form an alkene.

25. The formulation of claim 22 wherein R4 is —CH3.

26. The formulation of claim 22 wherein R10 is —C(CH2)CH3.

27. The formulation of claim 22 wherein R13 and R14 are H;

28. The formulation of claim 22 wherein R15 is an alkyl of 1-8 carbons.

29. The formulation of claim 28 wherein R15 is —(CH2)4CH3.

30. The formulation of claim 22 wherein each R16 independently represents H or —CH3.

31. The formulation of claim 22 wherein R17 is C(O)R18 wherein R18 represents the remnant of an acid or ester.

32. The formulation of claim 31 wherein R18 represents the remnant of salicylic acid, methyl salicylate, a carboxylic acid of 5 to 10 carbons, cinnamic acid, citric acid, retinoic acid, acetic acid, ascorbic acid, capric acid, and caprylic acid.

33. The formulation of claim 22 wherein each R19 is —CH3.

34. The formulation of claim 22 wherein each x is independently an integer of 3-13.

35. The formulation of claim 22 wherein said compound is defined by Formula I:

36. The formulation of claim 35 wherein each x is independently 3-13 and each R17 is independently selected from H, C(O)C6H4OH, —C(O)CH═CHC6H5, —C(O)(CH2)7CH3, or —(O)(CH2)9CH3.

37. The formulation of claim 36 wherein both R17 groups are the same.

38. The formulation of claim 22 wherein said compound is defined by Formula II:

39. The formulation of claim 38 wherein each x is independently 3-13 and each R17 is independently selected from H, C(O)C6H4OH, —C(O)CH═CHC6H5, —C(O)(CH2)7CH3, or —(O)(CH2)9CH3.

40. The formulation of claim 39 wherein both R17 groups are the same.

41. The formulation of claim 22 wherein said compound has an HLB of at least 8.

42. The formulation of claim 41 wherein said HLB is 12-16.

43. The formulation of claim 22 further comprising water.

44. The formulation of claim 22 wherein said cannabinoid is selected from the the group consisting of CBD, THC, cannabichromene (CBC), cannabichromevarin (CBCV), cannabidiphorol (CBDP), cannabidivarinic acid (CBDVA), cannabielsoin (CBEA), cannabigerolic acid (CBCA), cannabigerolic acid monomethyl ether (CBGAM), cannabigerovarinic acid (CBGVA), cannabicyclolic acid (CBLA), cannabinolic acid (CBNA), cannabicitranic acid (CBTA), cannabivarinic acid (CBVA), tetrahydrocannabinolic acid (THCA), tetrahydrocannabiorcolic acid (THCCA), tetrahydrocannabiphorolic acid (THCPA), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), cannadibiphorol (CBDP), cannabidivarin (CBDV), cannabielsoin (CBE), cannabigerol (CBG), cannabigerol monomethylether (CBGM), cannabigerovarin (CBG), cannabigerol monomethylether (CBGM), cannabigerovarin (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabicitran (CBTC), cannabivarin (CBV), tetrahydrocannabiorcol (THCC), tetrahydrocannabiphorol (THCP) or tetrahydrocannabivarin (TNCV).

45. The formulation of claim 22 wherein comprising hemp.

46. The formulation of claim 22 further comprising at least one additive selected from the group consisting of surfactants, emollients, lubricants, fragrances, colorants, flavorants, medications and natural oils.

47. The formulation of claim 46 further comprising at least one additive selected from the group consisting of coconut oil, olive oil, monoglycerides, diglycerides and triglycerides.

48. A method for treating tissue comprising applying a formulation comprising:

a compound defined by General Formula:

wherein:

R1-R10 are independently selected from H or an alkyl of 1-10 carbons; alkenyl of up to 10 carbons; or groups on adjacent carbons may be taken together to form an alkene;

R11 and R12 are independently H or —(CH2CHR16O)x—R17 with the proviso that at least one of R11 or R12 represents —(CH2CHR16O)xR17—; R11 and R10 may be taken together to represent —C(R19)2—;

R13-R15 independently represent H or an alkyl of 1-8 carbons;

each R16 independently represents H or an alkyl of 1-3 carbons;

each R17 independently represents H, an alkyl or substituted alkyl of 1-22 carbons, aryl or substituted aryl or the ester of an acid;

each R19 independently represents H or an alkyl of 1-5 carbons; and

each x is independently an integer of 1-100; and

a cannabinoid.

49. The method for treating tissue of claim 48 wherein R1, R5, R6, R7, R8 and R9 are H.

50. The method for treating tissue of claim 48 wherein R2 and R3 are taken together to form an alkene.

51. The method for treating tissue of claim 48 wherein R4 is —CH3.

52. The method for treating tissue of claim 48 wherein R19 is —C(CH2)CH3.

53. The method for treating tissue of claim 48 wherein R13 and R14 are H;

54. The method for treating tissue of claim 48 wherein R15 is an alkyl of 1-8 carbons.

55. The method for treating tissue of claim 54 wherein R15 is —(CH2)4CH3.

56. The method for treating tissue of claim 48 wherein each R16 independently represents H or —CH3.

57. The method for treating tissue of claim 48 wherein R17 is C(O)R18 wherein R18 represents the remnant of an acid or ester.

58. The method for treating tissue of claim 57 wherein R18 represents the remnant of salicylic acid, methyl salicylate, a carboxylic acid of 5 to 10 carbons, cinnamic acid, citric acid, retinoic acid, acetic acid, ascorbic acid, capric acid, and caprylic acid.

59. The method for treating tissue of claim 48 wherein each R19 is —CH3.

60. The method for treating tissue of claim 48 wherein each x is independently an integer of 3-13.

61. The method for treating tissue of claim 48 wherein said compound is defined by Formula I:

62. The method for treating tissue of claim 61 wherein each x is 3-13 and each R17 is independently selected from H, C(O)C6H4OH, —C(O)CH═CHC6H5, —C(O)(CH2)7CH3, or —(O)(CH2)9CH3.

63. The method for treating tissue of claim 62 wherein both R17 groups are the same.

64. The method for treating tissue of claim 48 wherein said compound is defined by Formula II:

65. The method for treating tissue of claim 17 wherein each x is 3-13 and each R17 is independently selected from H, C(O)C6H4OH, —C(O)CH═CHC6H5 or —C(O)(CH2)7CH3.

66. The method for treating tissue of claim 65 wherein both R17 groups are the same.

67. The method for treating tissue of claim 48 wherein said compound has an HLB of at least 8.

68. The method for treating tissue of claim 67 wherein said HLB is 12-16.

69. The method for treating tissue of claim 48 further comprising water.

70. The method for treating tissue of claim 48 wherein said cannabinoid is selected from the group consisting of CBD, THC, cannabichromene (CBC), cannabichromevarin (CBCV), cannabidiphorol (CBDP), cannabidivarinic acid (CBDVA), cannabielsoin (CBEA), cannabigerolic acid (CBCA), cannabigerolic acid monomethyl ether (CBGAM), cannabigerovarinic acid (CBGVA), cannabicyclolic acid (CBLA), cannabinolic acid (CBNA), cannabicitranic acid (CBTA), cannabivarinic acid (CBVA), tetrahydrocannabinolic acid (THCA), tetrahydrocannabiorcolic acid (THCCA), tetrahydrocannabiphorolic acid (THCPA), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), cannadibiphorol (CBDP), cannabidivarin (CBDV), cannabielsoin (CBE), cannabigerol (CBG), cannabigerol monomethylether (CBGM), cannabigerovarin (CBG), cannabigerol monomethylether (CBGM), cannabigerovarin (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabicitran (CBTC), cannabivarin (CBV), tetrahydrocannabiorcol (THCC), tetrahydrocannabiphorol (THCP) or tetrahydrocannabivarin (TNCV).

71. The method for treating tissue of claim 48 wherein comprising hemp.

72. The method for treating tissue of claim 48 further comprising at least one additive selected from the group consisting of surfactants, emollients, lubricants, fragrances, colorants, flavorants, medications and natural oils.

73. The method for treating tissue of claim 72 further comprising at least one additive selected from the group consisting of coconut oil, olive oil, monoglycerides, diglycerides and triglycerides.

74. The method for treating tissue of claim 72 wherein said treatment is for acne regulation, cell renewal and regeneration, epidermal barrier formulations, extracellular matrix integrity formulations, pigmentation regulation or melanogenesis, for skin hydration, tissue remodeling, wound healing, insulin signaling, pain treatment, inflammation mitigation, immune response, circadian rhythm treatments, anti-oxidant stress relief, CB1 partial agonist, emmolient or humectant, skin brightening, as a barrier cream, as a skin protectant, and an sun protection factor (SPF) enhancer, as a film former or as a fragrance fixative.